- 专利标题： N-(2-(4-cyanothiazolidin-3-yl)-2-oxoethyl)-quinoline-4-carboxamides
-
申请号： US18332897申请日： 2023-06-12
-
公开(公告)号： US11858924B2公开(公告)日： 2024-01-02
- 发明人: Jonas Brånalt , Maria Johansson , Anneli Nordqvist , Marianne Swanson
- 申请人： AstraZeneca AB
- 申请人地址： SE Södertälje
- 专利权人： AstraZeneca
- 当前专利权人： AstraZeneca
- 当前专利权人地址： SE Södertälje
- 主分类号： C07D417/12
- IPC分类号： C07D417/12 ; A61P1/16
摘要：
Compounds having the structure of Formula (I):
and pharmaceutically acceptable salts thereof, wherein X1, R1, R2, R3, R4, R5 and R6 are as defined in the specification; pharmaceutical compositions comprising such compounds and salts; use of such compounds and salts to treat or prevent Prolyl endopeptidase fibroblast activation protein (FAP)-mediated conditions; kits comprising such compounds and salts; and methods for manufacturing such compounds and salts.
and pharmaceutically acceptable salts thereof, wherein X1, R1, R2, R3, R4, R5 and R6 are as defined in the specification; pharmaceutical compositions comprising such compounds and salts; use of such compounds and salts to treat or prevent Prolyl endopeptidase fibroblast activation protein (FAP)-mediated conditions; kits comprising such compounds and salts; and methods for manufacturing such compounds and salts.
公开/授权文献
信息查询
